Read More Pharma Industry News Sangamo Therapeutics shares surge 13% after FDA accepts rolling BLA for ST‑920 in Fabry disease Sangamo Therapeutics shares surged 13% as the FDA accepted a rolling BLA for ST‑920 in Fabry disease. Learn what this milestone means and what’s next. bySrinathNovember 21, 2025